Ron DePinho: CRISPR Progress in Cellular Immunotherapy
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn about a recent article by Heidi Ledford, adding:
”CRISPR progress in cellular immunotherapy …
Researchers used a combination of engineered viruses and virus-like particles to target T cells. The particles carried RNA and protein machinery needed for CRISPR–Cas9 gene editing, and the viruses contained the DNA encoding the CAR protein. T cells had to receive both payloads to become a CAR T cell.
In mice with leukaemia and multiple myeloma, tumors were completely wiped out in the treated mice, and more than half of the treated group with sarcomas entered full remission. A biotechnology company, Azalea Therapeutics is now testing the approach in monkeys and hopes to have clinical trials in people by the end of next year. While encouraging, it remains to be seen how long the effects of the treatment last, or whether CRISPR–Cas9 might be introducing any unwanted changes to the genome.”
Title: CRISPR makes enhanced cancer-fighting immune cells inside mice
Author: Heidi Ledford
Read the Full Article on Nature
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation